Compare Sana Biotechnology Inc (SANA) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Suncor Energy Inc. — how do they compare? Sana Biotechnology Inc trades at $3.75 (market cap $1.13B), while Suncor Energy Inc. trades at $63.83 (market cap $74.07B). The key difference: Suncor Energy Inc. is far larger — about 65.5× Sana Biotechnology Inc's market cap, and Suncor Energy Inc. pays a 2.7% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SU | |
|---|---|---|
Market Cap | $1.13B | $74.07B |
Sector | Health | Energy |
52-Week High | $5.92 | $69.73 |
52-Week Low | $2.68 | $38.17 |
Enterprise Value | $1.05B | $80.75B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Suncor Energy (SU) trades at $62.73, up 4.38% today, with a bearish technical signal but strong fundamentals including a P/E of 11.79 and net margin of 14.7%. Recent Q2 2026 earnings beat estimates at $2.27 EPS, driven by higher crude realizations and refining margins (Reuters, 2026-08-04). The company maintains a consistent dividend of $0.60 per share and announced a CEO transition to Peter Zebedee in 2027.
Outlook is supported by solid cash flow and buybacks, but risks include commodity price volatility and operational disruptions. Analyst consensus is strongly bullish with 74% buy ratings, targeting upside from efficient operations and debt reduction, though technical weakness near support at $61 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
